Skip to content
Aimovig(erenumab)
Aimovig (erenumab) is an antibody pharmaceutical. Erenumab was first approved as Aimovig on 2018-05-17. It has been approved in Europe to treat migraine disorders. It is known to target calcitonin gene-related peptide type 1 receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
Trade Name
FDA
EMA
Aimovig
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Erenumab
Tradename
Proper name
Company
Number
Date
Products
Aimovigerenumab-aooeAmgenN-761077 RX2018-05-17
4 products
Labels
FDA
EMA
Brand Name
Status
Last Update
aimovigBiologic Licensing Application2021-02-11
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
N02: Analgesics
N02C: Antimigraine preparations
N02CD: Calcitonin gene-related peptide (cgrp) antagonists
N02CD01: Erenumab
HCPCS
No data
Clinical
Clinical Trials
60 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Migraine disordersD008881EFO_0003821G4372916741
HeadacheD006261HP_0002315R5111
Facial painD005157R51.911
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Post-traumatic headacheD051298G44.333
Brain concussionD001924S06.022
Temporomandibular joint disordersD013705M26.622
RosaceaD012393L7111
Post-concussion syndromeD038223EFO_1001827F07.8111
Trigeminal neuralgiaD014277EFO_1001219G50.011
Stable anginaD060050I20.811
Brain diseasesD001927HP_0001298G93.4011
Cluster headacheD003027HP_0012199G44.0011
Primary headache disordersD051270G44.5311
Show 4 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients11
Hot flashesD01958411
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Migraine without auraD020326EFO_0005296G43.022
Migraine with auraD020325EFO_0005295G43.122
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameERENUMAB
INNerenumab
Description
Erenumab, sold under the brand name Aimovig, is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine. It is administered by subcutaneous injection.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)ERENUMAB
Structure (InChI/SMILES or Protein Sequence)
>6UMH:H,h|erenumab Fab heavy chain, IgG1 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSIKYSVDSVKGRFTISRDNSKNTLF LQMNSLRAEDTAVYYCARDRLNYYDSSGYYHYKYYGMAVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDEVD >6UMH:L,l|erenumab Fab light chain, IgG1 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSTTLGITGLQ TGDEADYYCGTWDSRLSAVVFGGGTKLTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVK AGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
Identifiers
PDB6UMG, 6UMH, 6UMI, 6UMJ
CAS-ID1582205-90-0
RxCUI2045613
ChEMBL IDCHEMBL3833329
ChEBI ID
PubChem CID
DrugBankDB14039
UNII IDI5I8VB78VT (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CALCRL
CALCRL
Organism
Homo sapiens
Gene name
CALCRL
Gene synonyms
CGRPR
NCBI Gene ID
Protein name
calcitonin gene-related peptide type 1 receptor
Protein synonyms
calcitonin receptor-like, Calcitonin receptor-like receptor, CGRP type 1 receptor
Uniprot ID
Mouse ortholog
Calcrl (54598)
calcitonin gene-related peptide type 1 receptor (Q9WUP2)
Variants
Clinical Variant
No data
Financial
Aimovig - Novartis
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 972 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,525 adverse events reported
View more details